AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30243294 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/remifentanil-based total intravenous anesthesia (TIVA group)
Number of subjects: 80
Study 30243294 — intervention group
Group type: COMPARATOR
Intervention: Comparison of two groups
Number of subjects: 80
Study 26433523 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 226
Study 26433523 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 226
Study 24445147 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (625 mg/m² twice daily orally) + Streptozocin (1.0 g/m² intravenously on day 1)
Number of subjects: 86
Study 24445147 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (625 mg/m² twice daily orally) + Streptozocin (1.0 g/m² intravenously on day 1) + Cisplatin (70 mg/m² intravenously on day 1)
Number of subjects: 86
Study 22991109 — intervention group
Group type: EXPERIMENTAL
Intervention: Group educational activities using problematization methodology
Number of subjects: 62
Study 22991109 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 62
Study 20691266 — intervention group
Group type: EXPERIMENTAL
Intervention: PfCS102 (30 μg, twice)
Number of subjects: 16
Study 20691266 — intervention group
Group type: COMPARATOR
Intervention: ISA 720 (control)
Number of subjects: 16
Study 17899104 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged catheter drainage with negative pressure
Number of subjects: 40
Study 17899104 — intervention group
Group type: COMPARATOR
Intervention: Single-session alcohol sclerotherapy
Number of subjects: 40
Study 16873668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate plus thalidomide (arm C)
Number of subjects: 597
Study 16873668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (arm B)
Number of subjects: 597
Study 16873668 — intervention group
Group type: COMPARATOR
Intervention: No maintenance (arm A)
Number of subjects: 597
Study 12600851 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate, high-GI diet
Number of subjects: 34
Study 12600851 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate, low-GI diet
Number of subjects: 34
Study 12600851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-MUFA diet
Number of subjects: 34
Study 11286039 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral sumatriptan
Number of subjects: 233
Study 11286039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 8972000 — intervention group
Group type: EXPERIMENTAL
Intervention: Sak42D (15 mg each, double bolus, 30 min apart)
Number of subjects: 24
Study 8972000 — intervention group
Group type: COMPARATOR
Intervention: rt‐PA (accelerated weight-adjusted, maximum of 100 mg over 90 min)
Number of subjects: 24
Study 1600703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (0.3 U kg‐1, 0.6 U kg‐1, 0.8 U kg‐1)
Number of subjects: 11
Study 1600703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Number of subjects: 11
Study 1600703 — intervention group
Group type: COMPARATOR
Intervention: Intravenous insulin (4 U)
Number of subjects: 11
Study 1600703 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (6 U)
Number of subjects: 11
Study 2861219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg procaterol
Number of subjects: 45
Study 2861219 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg procaterol
Number of subjects: 45
Study 2861219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30346675 — intervention group
Group type: EXPERIMENTAL
Intervention: GC‐Europe (Aadva)
Number of subjects: 30
Study 30346675 — intervention group
Group type: EXPERIMENTAL
Intervention: True‐Definition‐TD
Number of subjects: 30
Study 30346675 — intervention group
Group type: EXPERIMENTAL
Intervention: Trios
Number of subjects: 30
Study 30346675 — intervention group
Group type: COMPARATOR
Intervention: Conventional impressions (Control)
Number of subjects: 30
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity prevalence
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Less than high school completion
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Needing health care but not receiving it
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective mental health
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Spent over $500 for drugs and alcohol in the past month
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/AIDS
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart disease
Number of subjects: 421
Study 27437937 — intervention group
Group type: EXPERIMENTAL
Intervention: Going to a drop‐in centre, community meal centre or program/food bank
Number of subjects: 421
Study 23515755 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernioplasty using acellular tissue matrix (ACTM) grafts
Number of subjects: 100
Study 23515755 — intervention group
Group type: COMPARATOR
Intervention: Traditional high ligation of the hernia sac (control group)
Number of subjects: 100
Study 24391822 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 114
Study 24391822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 20736432 — intervention group
Group type: EXPERIMENTAL
Intervention: ETTc pressure measured and adjusted
Number of subjects: 509
Study 20736432 — intervention group
Group type: COMPARATOR
Intervention: Control group without measuring ETTc pressure
Number of subjects: 509
Study 19008171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxy-Gen lite technology (pulsatile oxygen delivery)
Number of subjects: 32
Study 19008171 — intervention group
Group type: COMPARATOR
Intervention: Standard continuous oxygen therapy (maximal flow rate of 2 L/min)
Number of subjects: 32
Study 15705022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylated fatty acid (CFA) topical cream applied twice per day for 30 days
Number of subjects: 40
Study 15705022 — intervention group
Group type: COMPARATOR
Intervention: Placebo topical cream
Number of subjects: 40
Study 15705022 — intervention group
Group type: COMPARATOR
Intervention: CFA and Placebo (subgroup analysis)
Number of subjects: 40
Study 12573937 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) and Adderall
Number of subjects: 21
Study 12573937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10472228 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (285 mg)
Number of subjects: 80
Study 9096850 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) supplementation as sodium selenite
Number of subjects: 10
Study 1867580 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral intake of fluids (water, tea or coffee with sugar) without limitation of quantity
Number of subjects: 51
Study 1867580 — intervention group
Group type: COMPARATOR
Intervention: Fasting at least until 24 hours after the end of the operation
Number of subjects: 51
Study 7052613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) administered subcutaneously equivalent to 5 x 10^8 lymphocytes, given twice at one week intervals and then every four weeks thereafter.
Number of subjects: 0
Study 7052613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) group
Number of subjects: 0
Study 30862118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor-led text-messaging intervention
Number of subjects: 411
Study 30862118 — intervention group
Group type: COMPARATOR
Intervention: Delayed control (no text messages)
Number of subjects: 411
Study 29136630 — intervention group
Group type: EXPERIMENTAL
Intervention: Catcher Tagged group (TAG)
Number of subjects: 64
Study 29136630 — intervention group
Group type: COMPARATOR
Intervention: Net forceps group (NET)
Number of subjects: 64
Study 27222459 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-guided self-learning programme (bibliotherapy) in addition to usual care
Number of subjects: 116
Study 25200559 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) plus optimised clinical treatment (OCT)
Number of subjects: 60
Study 25200559 — intervention group
Group type: COMPARATOR
Intervention: Optimised clinical treatment (OCT) alone
Number of subjects: 60
Study 22362922 — intervention group
Group type: EXPERIMENTAL
Intervention: State anxiety induction task
Number of subjects: 110
Study 22362922 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 110
Study 19647342 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g)
Number of subjects: 146
Study 19647342 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg)
Number of subjects: 146
Study 19647342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 146
Study 17725934 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of lorazepam (n=47)
Number of subjects: 95
Study 17725934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=48)
Number of subjects: 95
Study 15185267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for bulimia nervosa
Number of subjects: 80
Study 12186124 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 48
Study 12186124 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 48
Study 9524424 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactive phase of SLE pregnancies
Number of subjects: 75
Study 9524424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematological autoimmune presentations (APA)
Number of subjects: 75
Study 9524424 — intervention group
Group type: EXPERIMENTAL
Intervention: Any kind of hemocytopenias without APA
Number of subjects: 75
Study 9524424 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 8595188 — intervention group
Group type: EXPERIMENTAL
Intervention: Right unilateral brain-damaged patients with neglect
Number of subjects: 4
Study 8595188 — intervention group
Group type: COMPARATOR
Intervention: Left and right patients without neglect or hemianopia
Number of subjects: 4
Study 8595188 — intervention group
Group type: COMPARATOR
Intervention: Patients with left or right retrogeniculate lesions and lateral homonymous hemianopia
Number of subjects: 4
Study 2565346 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (small repeated doses)
Number of subjects: 35
Study 2565346 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (small repeated doses) + haloperidol 15 mg
Number of subjects: 35
Study 2565346 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 35
Study 100866 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. TRH infusion (0.66 mg/hour) for 3 hours
Number of subjects: 6
Study 30993840 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 150
Study 30993840 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel warming
Number of subjects: 150
Study 30993840 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 28085236 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg
Number of subjects: 100
Study 28085236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 26407587 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemic night (PG target of 2.7-2.8 mmol/L maintained for 15 min)
Number of subjects: 26
Study 26407587 — intervention group
Group type: COMPARATOR
Intervention: Normoglycemic night (PG maintained at 5.0-7.0 mmol/L)
Number of subjects: 26
Study 23704674 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 699
Study 23704674 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 699
Study 23704674 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus lifestyle
Number of subjects: 699
Study 23704674 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (irrespective of group)
Number of subjects: 699
Study 21802658 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil (MOR agonist)
Number of subjects: 22
Study 21802658 — intervention group
Group type: COMPARATOR
Intervention: healthy control subjects
Number of subjects: 22
Study 19101253 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-led feedback
Number of subjects: 32
Study 19101253 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control)
Number of subjects: 32
Study 17615281 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg three times a day for 24 hours)
Number of subjects: 0
Study 17615281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15131431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-intervention (A)
Number of subjects: 164
Study 15131431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-intervention plus worksite visit (B)
Number of subjects: 164
Study 15131431 — intervention group
Group type: COMPARATOR
Intervention: Usual care (C)
Number of subjects: 164
Study 15131431 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-intervention (A) and Mini-intervention plus worksite visit (B)
Number of subjects: 164
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Inland territory (goiter prevalence)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea level (goiter prevalence)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal TSH levels (inland territory)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal TSH levels (sea level)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine excretion (inland territory)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine excretion (sea level)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Median urinary iodine excretion (inland villages)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Median urinary iodine excretion (Crotone)
Number of subjects: 13984
Study 11936460 — intervention group
Group type: EXPERIMENTAL
Intervention: Median urinary iodine excretion (Reggio Calabria)
Number of subjects: 13984
Study 9649661 — intervention group
Group type: EXPERIMENTAL
Intervention: 1alpha,25-dihydroxyvitamin D3 (VD3)
Number of subjects: 0
Study 8021472 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g purified fish oil once a day for 6 months
Number of subjects: 350
Study 8021472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 2511253 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples from HIV-1 seropositive individuals
Number of subjects: 48
Study 2511253 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood mononuclear cell samples
Number of subjects: 48
Study 2511253 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine samples for HIV-1 p24 antigen by ELISA
Number of subjects: 48
Study 2511253 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral blood samples for serum HIV-1 p24 antigen
Number of subjects: 48
Study 28749254 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate training (60% MAP, 5 min blocks with 1 min recovery)
Number of subjects: 34
Study 28749254 — intervention group
Group type: EXPERIMENTAL
Intervention: High training (100% MAP, 2 min with 3 min recovery)
Number of subjects: 34
Study 28749254 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed training (two moderate and two high-intensity sessions weekly)
Number of subjects: 34
Study 27609854 — intervention group
Group type: EXPERIMENTAL
Intervention: INSD ketamine (1 mg/kg)
Number of subjects: 80
Study 27609854 — intervention group
Group type: COMPARATOR
Intervention: IN fentanyl (1.5 μg/kg)
Number of subjects: 80
Study 25917674 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine (Rotarix)
Number of subjects: 120
Study 25917674 — intervention group
Group type: COMPARATOR
Intervention: Sucrose solution (Tootsweet)
Number of subjects: 120
Study 23064291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multifactorial treatment (IT)
Number of subjects: 1533
Study 23064291 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 1533
Study 20601159 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper advertisements
Number of subjects: 197
Study 20601159 — intervention group
Group type: EXPERIMENTAL
Intervention: Posters
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Family physician recruiters
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Family physician referrals
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Community presentations
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Community events
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Newsletters
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Direct mailings
Number of subjects: 197
Study 20601159 — intervention group
Group type: COMPARATOR
Intervention: Word of mouth
Number of subjects: 197
Study 18379218 — intervention group
Group type: EXPERIMENTAL
Intervention: HiMF training (HiMFT)
Number of subjects: 49
Study 18379218 — intervention group
Group type: EXPERIMENTAL
Intervention: LoMF training (LoMFT)
Number of subjects: 49
Study 18379218 — intervention group
Group type: COMPARATOR
Intervention: HiMF control (HiMFC)
Number of subjects: 49
Study 18379218 — intervention group
Group type: COMPARATOR
Intervention: LoMF control (LoMFC)
Number of subjects: 49
Study 15722811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic whiplash‐associated disorders
Number of subjects: 69
Study 15722811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic idiopathic neck pain
Number of subjects: 69
Study 15722811 — intervention group
Group type: COMPARATOR
Intervention: Control group (pain-free volunteers)
Number of subjects: 69
Study 12917125 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fractal analysis of CBF SPECT images in AD patients
Number of subjects: 74
Study 12917125 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fractal analysis of CBF SPECT images in VaD patients
Number of subjects: 74
Study 12917125 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 74
Study 12917125 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of A/P ratio in AD patients
Number of subjects: 74
Study 12917125 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of A/P ratio in VaD patients
Number of subjects: 74
Study 10532588 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD59 immunocytochemistry
Number of subjects: 8
Study 10532588 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-MCP immunocytochemistry
Number of subjects: 8
Study 10532588 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-DAF immunocytochemistry
Number of subjects: 8
Study 10532588 — intervention group
Group type: EXPERIMENTAL
Intervention: CR1 detection
Number of subjects: 8
Study 10532588 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ hybridization for CD59, MCP, DAF, and CR1 mRNA
Number of subjects: 8
Study 10532588 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse transcriptase-polymerase chain reaction
Number of subjects: 8
Study 8558644 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMV chemotherapy (cisplatin, methotrexate, vinblastine)
Number of subjects: 50
Study 8558644 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 50
Study 8558644 — intervention group
Group type: EXPERIMENTAL
Intervention: CMV chemotherapy for salvage after relapse
Number of subjects: 50
Study 1869388 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (2 gr)
Number of subjects: 103
Study 1869388 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin (100 mg)
Number of subjects: 103
Study 7041150 — intervention group
Group type: EXPERIMENTAL
Intervention: Early excision and grafting within 5 days after the burn
Number of subjects: 0
Study 7041150 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment with topical chemotherapy and hydrotherapy
Number of subjects: 0
Study 31242190 — intervention group
Group type: EXPERIMENTAL
Intervention: Water treatment
Number of subjects: 9077
Study 31242190 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved sanitation
Number of subjects: 9077
Study 31242190 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing with soap
Number of subjects: 9077
Study 31242190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined water treatment, sanitation, and handwashing (WSH)
Number of subjects: 9077
Study 31242190 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved nutrition
Number of subjects: 9077
Study 31242190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined WSH and nutrition (WSHN)
Number of subjects: 9077
Study 31242190 — intervention group
Group type: COMPARATOR
Intervention: Control group (received household visits but no interventions)
Number of subjects: 9077
Study 28873118 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical timolol
Number of subjects: 0
Study 28873118 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 26233235 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Contact
Number of subjects: 103
Study 26233235 — intervention group
Group type: COMPARATOR
Intervention: Self-Help
Number of subjects: 103
Study 26233235 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 24480899 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day intensive cognitive therapy for PTSD
Number of subjects: 121
Study 24480899 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of standard weekly cognitive therapy
Number of subjects: 121
Study 24480899 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 months of weekly emotion-focused supportive therapy
Number of subjects: 121